VanEck Australian Floating Rate ETF vs Tilray Brands Inc — how do they compare? VanEck Australian Floating Rate ETF trades at $50.96 (market cap $11.24B), while Tilray Brands Inc trades at $3.63 (market cap $530.54M). The key difference: VanEck Australian Floating Rate ETF is far larger — about 21.2× Tilray Brands Inc's market cap, and VanEck Australian Floating Rate ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Australian Floating Rate ETF for 21 Days and Tilray Brands Inc for 31 Days on average.
| FLOT | TLRY | |
|---|---|---|
Market Cap | $11.24B | $530.54M |
Volume | 1,872,962 | 9,099,075 |
Sector | Fixed Income | Health |
52-Week High | $51.07 | $21.00 |
52-Week Low | $50.72 | $3.57 |
Typical Hold Time | 21 Days | 31 Days |
Enterprise Value | — | $684.46M |
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.91 with minimal daily movement (-0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. Recent dividend distributions of $0.17-$0.18 highlight income generation. The ETF benefits from floating rate exposure amid Fed tightening cycles, though concentration risk in bank holdings (47% exposure) warrants attention.
Outlook remains tied to interest rate trajectory, with FLOT positioned to benefit from higher rates. Key risks include bank sector concentration and Fed policy shifts. The current technical weakness suggests cautious near-term momentum despite the floating rate advantage in rising rate environments.
TLRY trades at $3.715, down 1.72% on the day and near its 52-week low, reflecting persistent bearish technical momentum. The company reported revenue of $821.31M in 2025 but a substantial net loss of -$2.19B, with negative cash flow from operations. Recent quarters show consistent earnings misses versus expectations, though analyst consensus suggests a high price target of $65.01 amid mixed sentiment.
The outlook remains challenged by profitability issues and high debt, but potential catalysts include U.S. cannabis regulatory changes. Investment opportunities hinge on speculative regulatory shifts, while risks include ongoing losses, competitive pressures, and reliance on financing activities to sustain operations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →